Rob Masella is a partner in the firm’s Life Sciences group and Public M&A and Corporate Governance practice. He has extensive experience in U.S. and cross-border corporate transactions, representation of Boards of Directors, and corporate governance matters. His transactional work includes public and private mergers and acquisitions, sell-side and buy-side transactions, dual-track M&A/IPO processes, joint ventures, licenses, co-promotion agreements, debt and equity investments and issuances, spin-offs and other forms of corporate transactions. Mr. Masella also regularly represents technology companies in M&A transactions and investment banks in financial advisory assignments. His corporate governance practice includes advising clients with respect to shareholder activism, corporate governance and fiduciary duty matters, disclosure obligations, conflicts-of-interest and compliance matters.
Areas of Practice
Domaines D’Expertise





Mr. Masella’s representative experience includes:

  • Caris Life Sciences in over $1 billion of growth equity financing.*
  • AcelRx in its acquisition of Lowell Therapeutics*
  • Intapp in its Initial Public Offering.*
  • MeiraGTx Holdings plc in its acquisition of Emrys Bio Inc.*
  • Alnylam in various corporate governance matters.*
  • AcelRx in various corporate matters.*
  • Ultragenyx in its investment in Arcturus Therapeutics.*
  • Sonic Corp. in its sale to Inspire Brands.*
  • Intapp in its acquisition of Repstor Limited.*
  • Thomson Reuters in various acquisition transactions, including in the acquisition of Redi Technologies and Capital Confirmation.*
  • Thomson Reuters in various divestiture transactions, including the sale of Gardiner-Caldwell, Physician's World, Physicians' Desk Reference and Scientific Connexions.*
  • Intapp in its acquisition of OnePlace.*
  • Intapp in its acquisition of DealCloud.*
  • Knauf in its acquisition of USG Corporation for $7 billion.*
  • Knauf in its withhold campaign at USG Corporation.*
  • Equilibre Pharma in multiple equity financings.*
  • Retromer Pharma in multiple equity financings.*
  • Inspirna in various collaborations.*
  • MedeAnalytics in its acquisition of assets from The Advisory Board Company.*
  • MedeAnalytics, a portfolio company of Bain Capital, in its sale to Thoma Bravo LLC.*
  • MedeAnalytics in its acquisition of OnFocus Healthcare.*
  • Shareholder of Interactive Data in its sale to the Intercontinental Exchange.*
  • Supreme Oil in its sale to Stratas Foods.*
  • Icopal in its sale to GAP.*
  • Mitsubishi in its $5.39 billion acquisition from Anglo American plc of a 24.5% interest in Anglo American Sur, a Chilean copper mining company.*
  • iParadigms, a portfolio company of Warburg Pincus, in its $752 million sale to Insight Venture Partners and GIC Special Situations.*
  • Milestone Apartments Real Estate Investment Trust, as U.S. special counsel, in connection with its agreement to internalize its asset management business.*
  • Citibank in its sale of EMI Music to Universal Music Group and EMI Music Publishing to a consortium of investors.*
  • Bristol-Myers Squibb in its acquisition of DuPont Pharmaceuticals.*
  • Henry Schein in its investment in, and joint venture with, Maravet.*
  • Johnson & Johnson in its acquisition of Innovasive Devices.*
  • Oracle Corporation in its acquisition of Front Porch Digital.*
  • Hakkasan on its joint venture with MGM Resorts.*
  • Abertis Infraestructuras on the sale of Belfast International airport, Stockholm Skavsta airport, its Orlando airport terminal concession and its airport management business in the U.S.*
  • Platinum Equity on the acquisition of outdoor media assets from CBS Corporation.*
  • Riverside Partners on the acquisition of Bohemia Interactive Solutions.*
  • Quadriga Capital on the acquisition of Kinetic Systems.*
  • The special committee of Six Flags Entertainment in connection with the company's bankruptcy and assessment of competing plans of reorganization.*
  • iCrossing in the company's sale to the Hearst Corporation.*
  • Openwave in the sale of its mobile messaging and mediation businesses to Marlin Equity Partners.*
  • Lindsay, Goldberg in its acquisition of First American Payment Systems.*
  • Ecolochem in its ultra clean water joint venture with Nalco and Ecolochem's sale to Ionics.*
  • The John Frieda Companies in their sale to Kao Corporation.*
  • Conoco in its merger with Phillips Petroleum.*
  • EchoStar in its spin-off from Dish Network.*
  • Global Signal in its merger with Crown Castle.*
  • Jones Apparel in its hostile acquisition of Maxwell Shoe.*
  • Media General in the sale of a number of television markets.*
  • Nestle in its merger with Ralston Purina.*
  • Morgan Stanley in connection with a number of financial advisory assignments.* 

*Denotes experience prior to joining Goodwin.

Professional Experience

Prior to joining Goodwin, Mr. Masella was a partner in the Mergers & Acquisitions practice at Shearman & Sterling. He was previously a Managing Director in the Mergers & Acquisitions group at Bank of America Merrill Lynch, where he advised companies on U.S. and cross-border M&A transactions and participated on the firm’s fairness opinion committee. Prior to Bank of America Merrill Lynch, he was in Mergers & Acquisitions and corporate at Cravath, Swaine & Moore for nearly a decade. Mr. Masella began his career at Lehman Brothers as a Financial Analyst.

Professional Activities

Mr. Masella is a member of the Business Law Partner Advisory Board of Thomson Reuters Accelus, the National Advisory Committee of the Colonial Williamsburg Foundation, the New York Bar Association’s Committee on Mergers & Acquisitions and Corporate Control Contests, Law360’s Life Sciences Editorial Advisory Board and the New York Bar Association’s Corporation Law Committee.

In The News









University of Pennsylvania Law School
(magna cum laude)
The Wharton School at the University of Pennsylvania
(with distinction)
B.A., Economics
The College of William and Mary
(magna cum laude)
General Course Certificate
London School of Economics and Political Science



New York
Profile Image
Get In Touch
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.


Nos équipes interviennent aux côtés de nos clients, industriels, fonds d’investissement, startups, institutions financières et dirigeants, dans le cadre de transactions et de contentieux complexes, et apportent des conseils de tout premier plan dans les secteurs financiers, des Sciences de la Vie, du Private Equity, de l’immobilier et des technologies. Nous traitons les dossiers juridiques de manière intègre, ingénieuse, souple et audacieuse pour répondre efficacement aux enjeux propres à chacun de nos clients, quels que soient la taille de l’opération et le secteur d’activité. Pour en savoir plus, contactez-nous.

Unsere Kunden verlassen sich auf unsere erstklassige Beratung, vor allem im Hinblick auf komplexe Transaktionen und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Branchen, verwenden wir einen kooperativen und interdisziplinären Ansatz, um Fragen unserer Kunden auch in extremen Spezialsituationen einer Lösung zuzuführen. Sie wollen mehr erfahren? Kontaktieren Sie uns gerne.

Search Other Lawyers
Recherche par Pratique